Interferon-a (IFN-a) is used to treat chronic hepatitis B virus (HBV) infection, but only 20%-40% of patients respond well. Clinical observations have suggested that HBV genotype is associated with the response to IFN therapy; however, its role in viral responsiveness to IFN in HBV-infected hepatocytes remains unclear. Here, we produced infectious virions of HBV genotypes A to D to infect three well-recognized cell-culture-based HBV infection systems, including primary human hepatocytes (PHH), differentiated HepaRG (dHepaRG), and HepG2-NTCP cells to quantitatively compare the antiviral effect of IFN-a on HBV across genotypes and cell models. The efficacy of IFN-a against HBV in hepatocytes was generally similar across genotypes A2, B5, C2, and D3; however, it was significantly different among the infection models given that the half maximal inhibitory concentration value of IFN-a for inhibition of viral DNA replication in PHH (<20 U/mL) and dHepaRG cells were much lower than that in HepG2-NTCP cells (>500 U/mL). Notably, even in PHH, IFN-a did not reduce HBV covalently closed circular DNA at the concentrations for which viral antigens and DNA replication intermediates were strongly reduced. The three cell-culture models exhibited differential cellular response to IFN-a. The genes reported to be associated with responsiveness to IFN-a in patients were robustly induced in PHH while weakly induced in HepG2-NTCP cells upon IFN-a treatment. Reduction or promotion of IFN response in PHH or HepG2-NTCP cells significantly attenuated or improved the inhibitory capacity of IFN-a on HBV replication, respectively. Conclusion: In the cell-culture-based HBV infection models, the sensitivity of HBV to IFN-a in hepatocytes is determined more by the cell-intrinsic IFN response than by viral genotype, and improvement of the IFN response in HepG2-NTCP cells promotes the efficacy of IFN-a against HBV. (HEPATOLOGY 2018; 67:1237-1252).
H epatitis B virus (HBV) is a hepatotropic partially double-stranded DNA virus. Despite the availability of effective vaccines, chronic hepatitis B (CHB) virus infection, affecting approximately 240 million people worldwide, remains a health burden and is the main risk factor for the development of liver cirrhosis and hepatocellular carcinoma. Based on 8% sequence divergence of the entire 3.2-kilobase genome, HBV isolates worldwide can be grouped into at least nine genotypes (A-I) and numerous subgenotypes, of which the geographical distributions are quite distinct. The major genotypes worldwide are A to D. Genotypes Abbreviations: A3G, APOBEC3G; ANOVA, analysis of variance; cccDNA, covalently closed circular DNA; CHB, chronic hepatitis B; CHX, cycloheximide; CLIA ELISA, chemiluminescence immunoassay against enzyme-linked immunosorbent assay; CXCL10, C-X-C motif chemokine 10; dHepaRG, differentiated HepaRG; GBP, guanylate binding protein; HBs, hepatitis B surface; HBV, hepatitis B virus; HBeAg, HBV e antigen; HBsAg, HBV surface antigen; IC 50 , half maximal inhibitory concentration; IFITM, interferon-induced transmembrane protein; IFNAR, IFN-a receptor; IRF9, interferon regulatory factor 9; ISGs, interferon-stimulated genes; JAK, Janus kinase; OAS1, 2 0 -5 0 -oligoadenylate synthetase 1; PEG-IFN-a, pegylated IFN-a; pgRNA, pregenomic RNA; PHH, primary human hepatocyte; STAT, signal transducer and activator of transcription; TNFSF13B, tumor necrosis factor (ligand) superfamily, member 13B; TYK, tyrosine kinase; vge, viral genome equivalents; WARS, tryptophanyl-tRNA synthetase.
A and D are the two most prevalent genotypes in Europe, whereas genotypes B and C are the two dominant genotypes prevalent in eastern Asia and Oceania. (1) Interferon alpha (IFN-a) was initially discovered 60 years ago because of its ability to interfere with viral replication and has been demonstrated to induce multiple interferon-stimulated genes (ISGs) to inhibit HBV replication by affecting multiple steps of the viral life cycle in HBV-infected hepatocytes. It also has immunomodulatory activities that modulate the immune responses to HBV infection. (2, 3) By binding to IFN-a receptor (IFNAR) 1 and IFNAR2 on the cell surface, IFN-a leads to the activation of Janus kinase (JAK) 1 and tyrosine kinase (TYK) 2, which, in turn, phosphorylate a single tyrosine residue of signal transducer and activator of transcription (STAT) 1 and STAT2. Activated STAT1 and STAT2 heterodimerize with interferon regulatory factor 9 (IRF9) to form the ISGF3 transcription factor complexes and then translocate into the nucleus to initiate transcription of ISGs. (4) Administration of IFN-a and its pegylated form (PEG-IFN-a) to patients chronically infected with HBV has been widely used in the clinic; however, only 20%-40% of patients have HBV e antigen (HBeAg) seroconversion after 48 weeks of treatment. (5, 6) Both viral and host factors have been implicated in affecting the responsiveness to IFN-a therapy. Evidence from the clinic suggests that factors including female sex, higher baseline alanine aminotransferase levels, and low baseline HBV-DNA levels are associated with the prognostic parameters for sustained response following IFN therapy. (7) Moreover, HBV genotype A and B were found to be associated with better response to IFN treatment in CHB patients compared with genotype D and C, respectively. (8, 9) This has been supported by studies using transient transfection-based cell and mouse models (10) ; however, the intrinsic weakness of these models that do not allow study of the complete viral life cycle make it difficult to reach solid conclusions. As the major target of HBV infection, hepatocytes are equipped with relatively intact pattern recognition receptors and an IFN system and can initiate robust innate immune responses. (11) (12) (13) It has been shown that hepatocytes alone can induce HBV antigen decline during IFN-a administration, in the absence of an adaptive immune response. (14) In turn, HepaRG hepatocytes transduced with baculovirus expressing the HBV genome can mount an innate response, followed by an IFN-driven control of HBV replicative intermediates. (15) However, the role of HBV genotype in determining the response of HBV to IFN therapy in HBV-infected hepatocytes remains to be investigated.
Here, we produced infectious virions of HBV genotypes A to D to infect three well-characterized cellculture-based models. (16, 17) 
Materials and Methods

CELLS, ANTIBODIES, AND REAGENTS
HepG2, HepG2-NTCP (kindly provided by Yi Ni and Stephan Urban), dHepaRG, and PHH (Bioreclamation IVT, USA) were cultured as described. (18) Antibodies used here are listed in Supporting Table  S2 . The primers used for qPCR were synthesized by Biosune (Shanghai) and the primer sequences are listed in Supporting Table S3 . IFN-a (2a) (PBL Assay Science, USA), PEG-IFN-a-2a (Pegasys; Roche, Shanghai), cycloheximide (CHX; Sigma, USA), and tofacitinib (Selleck, USA) were purchased from the indicated manufacturers. Recombinant human IFN-a2 and IFN-a14 were produced as we described. (19) PLASMIDS, VIRUS PRODUCTION, AND IN VITRO VIRAL INFECTION The 1.3 mer HBV-DNA constructs for genotypes A2, B5 (formerly named as B6), and D3 were prepared by Genscript USA, as we described. (20) HBV surface antigen (HBsAg) and HBeAg levels in the cell-culture supernatant were measured using the chemiluminescence immunoassay (CLIA) against enzyme-linked immunosorbent assay (ELISA; Autobio, China). HBV-DNA levels in culture medium or purified HBV particles were extracted by the MagNA Pure 96 system (Roche, Switzerland), and then quantified by real-time PCR with universal primers and probe for HBV genome amplification across genotypes A to D. The vge copies were calculated based on a standard curve generated with known copy numbers. Cell viability was determined using the Cell Counting Kit-8 (CCK-8; Dojindo, Japan).
Hirt DNA EXTRACTION AND DETECTION OF HBV COVALENTLY CLOSED CIRCULAR DNA
HBV covalently closed circular DNA (cccDNA) was extracted from HBV-infected cells by a modified Hirt method as described. (21, 22) The HBV cccDNA in extracted Hirt DNA was either quantified by qPCR with specific primers or detected by Southern blotting analysis (for details, see the Supporting Methods).
REVERSE TRANSCRIPTION, REAL-TIME PCR ANALYSIS, IMMUNOFLUORESCENCE ASSAY, AND WESTERN BLOTTING ANALYSIS
Reverse transcription, real-time PCR analysis, immunofluorescence assay, and western blotting analysis are described in the Supporting Methods.
STATISTICAL ANALYSIS
Half maximal inhibitory concentration (IC 50 ) values were calculated using GraphPad Prism software (version 6; GraphPad Software Inc., USA). Significant differences were analyzed using a two-tailed unpaired t test or two-way analysis of variance (ANOVA) followed by Bonferroni's test to determine the differences in multiple comparisons. P values were calculated, and statistical significance is reported as P < 0.05 and P < 0.01). Data are presented as the mean 6 SD. Fig. S1 ). The infectivity of HBV genotype viruses from cell culture were tested in PHH. Viruses of HBV genotypes A2, B5, C2, and D3 showed good replication in PHH and thus they were used for further studies. At the same time, genotype D derived from the HepAD38 cells was included as control.
Results
HBV
In PHH, the kinetics of secreted HBsAg, HBeAg, and HBV DNA post-infection were measured (Fig.  1A ) and the HBsAg expression in infected cells was examined by immunostaining (Fig. 1B) . HBV-DNA levels in medium decreased at early time points analyzed post-infection, likely reflecting carryover DNA in the inoculum that was subsequently removed by washing and changing the medium. Because dHepaRG and HepG2-NTCP cells are also well-established infection cell systems for HBV, we further confirmed the infectivity and viral replication levels of the viruses using dHepaRG and HepG2-NTCP cells (Supporting Fig. S2 ). Secreted HBsAg, HBeAg, and DNA levels of HBV genotypes A2, B5, C2, and D3 at the endpoint in three hepatocyte cell infection systems are summarized in Supporting Table S1 . The overall viral replication levels of four genotypes were best in PHH, whereas they were lower in dHepaRG and HepG2-NTCP cells, particularly in HepG2-NTCP cells using transiently transfected derived virus, for reasons that are currently under investigation. Productive infection was only established in HepG2-NTCP cells using AD38-derived HBV genotype D. The levels of cccDNA in PHH were measured and examined by Southern blotting analysis (Fig. 1C) , which showed that cccDNA of A2, B5, C2, and D3 could be detected in infected PHH. The weak band of C2 may be attributed to lower HBV-DNA level compared to other genotypes. cccDNA of each genotype was confirmed by heat denaturation and further EcoRI digestion. Because B5 has a T-base change whereas others are G in the EcoRI recognition site, B5 exhibited as resistant to EcoRI digestion. Taken together, HBV virions of genotypes A2, B5, C2, and D3 were successfully produced, and although there were some differences in the productions of viral DNA and antigens among the four genotypes, they all established infection and replicated in PHH and dHepaRG cells.
DIFFERENCE IN THE OVERALL ANTI-HBV EFFECT OF IFN-a AMONG GENOTYPE A2/B5/C2/D3 IN PHH WAS NOT MARKED
Many clinical studies have reported that different HBV genotypes show different response rates to IFNa treatment. Given that multiple factors, including HBV genotypes and individual differences of patients, may contribute to treatment response in clinical studies, studies on the role of HBV genotype in response to IFN-a using more simplified in vitro infection systems are required. Therefore, based on the established effective infection of HBV genotype A2, B5, C2, and D3 in PHH, we further investigated the sensitivity of HBV in response to IFN-a in PHH. Anti-HBV activities of IFN-a on different HBV genotypes were assessed either with treatment before viral infection or post-infection ( Fig. 2A ). PHH were infected with genotypes A2, B5, C2, and D3 at the same viral genome equivalents (1,000 vge), respectively, and genotype D (derived from HepAD38 cells) was included at a lower (250 vge) viral genome equivalent to obtain similar viral replication levels. Although replication phenotype showed differences among the four HBV genotypes studied, IFN-a significantly reduced expression of HBsAg and HBeAg in all of them with treatment from day 3 to 12 post-infection in a dosedependent manner (Fig. 2B) . A marked inhibition (90% or greater) on secreted HBV DNA of four genotypes was observed even at the lowest dose (20 U/mL), which indicates that IFN-a treatment led to a stronger and faster HBV-DNA decline than HBsAg and HBeAg decline in HBV-infected PHH with 9 days of treatment. Preincubation with IFN-a for 24 hours before viral infection of different genotype viruses also showed significantly reduction of secreted HBsAg and HBeAg in a dose-dependent manner and they were similar across distinct genotypes (Fig. 2D ). IFN-a treatment with 3 doses (500, 100, and 20 U/mL) did not lead to detectable hepatotoxicity ( Fig. 2C and Supporting Fig. S4A ). Considering the high donorto-donor variability of PHH, we confirmed the effect of IFN-a on HBV across genotypes in PHH derived from another donor, and obtained similar results (Supporting Fig. S3 ). The susceptibility of each HBV genotype to IFN-a was further evaluated by determining IC 50 values of IFN-a based on the measurement of secreted HBsAg, HBeAg, and HBV DNA (Table 1) . Although statistically differences of HBsAg reduction in genotype A2 (P < 0.05), HBV DNA reduction in genotype B5 (P < 0.01), and HBsAg/HBeAg reduction in genotype D (P < 0.01) were observed, differences in the overall inhibitory effect of IFN-a on HBV replication across genotypes in PHH were not marked. Notably, a higher amount of HBV virions inoculated was found to be associated with less effectiveness of IFN-a (Fig. 2E) , which may explain the small differences observed in A2 and D in our system and is similar to the clinical observations that patients with higher viral load have lower responsiveness to IFN-a.
Next, the effects of IFN-a on cccDNA abundance in cells infected with HBV of different genotypes were examined. Unlike the report showing that IFN-a FIG. 1. Infection of PHH by HBV genotype A2, B5, C2, and D3, respectively. PHH were infected with HBV genotype A2, B5, C2, or D3 particles at same viral genome equivalents (1,000 vge) per cell. HepAD38-derived D (250 vge) was set as control. HBsAg, HBeAg, and HBV-DNA levels in medium at indicated time points post viral infection were measured by CLIA ELISA or quantified by qPCR (A). HBsAg (green) expression at day 12 was detected by immunofluorescence (B). HBV cccDNA levels in PHH infected with different HBV genotype were examined by Southern blotting (C), and the cccDNA was verified with heat denaturation or further EcoRI digestion before electrophoresis for Southern blotting analysis. Abbreviations: bp, base pairs; DAPI, 4 0 ,6-diamidino-2-phenylindole.
FIG. 2.
Anti-HBV activity of IFN-a on HBV genotype A2/B5/C2/D3/D in PHH. The anti-HBV effect of IFN-a (20, 100, and 500 U/mL) was evaluated with two different treatments (A). PHH infected with HBV genotype A2/B5/C2/D3 were either treated with IFN-a from days 3 to 12 post-HBV infection for 9-day treatment (B) or pretreated with IFN-a for 24 hours before viral infection (D). Extracellular HBsAg, HBeAg, and HBV-DNA levels with IFN-a treatments were evaluated at day 12. Cell viability of PHH with 9-day of IFN-a treatment post viral infection was determined (C). The antiviral effect of IFN-a (20 U/mL) associated with HBV replication levels were also checked on HBV genotype D with increased viral inoculum (E). Statistical analysis was performed with the Student t test. Data are shown as mean 6 SD (n 5 3). **P < 0.01; *P<0.05; ns, P > 0.05. Abbreviations: ns, not significant; PEIU, Paul Ehrlich Institute Units.
reduced HBV cccDNA in PHH and dHepaRG cells, (23) we did not observe reduction of HBV cccDNA under IFN-a treatment at the concentrations for which viral antigen expression and viral DNA replication intermediates were dramatically reduced in PHH (Fig. 3A) . Considering that PEG-IFN-a is currently more widely used in the clinic and has been shown to lead to better sustained responses in patients, we further examined the anti-HBV effect of PEG-IFN-a in vitro. Similar to that of IFN-a, whereas PEG-IFN-a treatment significantly inhibited HBV (genotype D) replication level, it showed a weak effect on reducing cccDNA level even in the dose of 360 ng/ mL (Fig. 3B) . Together, these results suggested that IFN-a did not much affect the level of cccDNA at the concentrations for which HBV-DNA replication and HBV antigens expression were strongly reduced in PHH.
ANTI-HBV ACTIVITY OF IFN-a SHOWED A STRIKING DIFFERENCE AMONG DISTINCT CELL-CULTURE SYSTEMS
To evaluate the host factors related to efficacy of IFN-a against HBV in hepatocytes, antiviral activities of IFN-a against four HBV genotypes were further examined in other hepatocyte cell-culture systems. dHepaRG cells were infected with HBV genotype A2, B5, C2, D3, and D, and further treated with IFN-a (500, 100, and 20 U/mL) for 9 days after viral infection (Fig. 4A) . Consistent with the results obtained in PHH, dose-dependent decline in HBsAg and HBeAg levels were observed and similar across the four genotypes (Fig. 4B) ; however, the reduction of viral DNA in response to IFN-a varied across HBV genotypes. HBV-DNA levels in the cell supernatant were found to be higher in genotype B5 and genotype D than that in genotype A2 and C2 (P < 0.01) in dHepaRG cells. Considering that there was a significant reduction of pregenomic RNA (pgRNA) in genotype D (data not shown), there may have been viral inoculum or inactive DNA attached to the cells. Quite different from PHH and dHepaRG cells, HepG2-NTCP cells were observed with poor anti-HBV effect in response to IFN-a on HBV genotype D (Fig. 4C) , and limited reduction was only observed with 500 U/mL of IFN-a. Although the replication levels of HBV genotype A2/B5/C2/D3 in HepG2-NTCP cells were low for reasons that are under investigation, similar poor anti-HBV effects of IFN-a were observed (Supporting Figs. S5 and S4B) . The calculated IC 50 values are summarized in Table 1 , and statistical analysis of the responsiveness to IFN-a among HBV genotypes were determined with multiple comparisons. Overall, these results suggest that whereas HBV genotypes showed minor influence on the anti-HBV effect of IFN-a, the IFN-a-mediated inhibition of HBV replication and antigens production showed a striking difference among distinct cell models. IC 50 values were calculated with Graphpad Prism; statistical analysis was performed by two-way ANOVA (IFN-a concentration and HBV genotypes) for multiple comparisons. *P < 0.01, as compared with other viruses. † P < 0.01, as compared with B5, C2, and D3. ‡ P < 0.05, as compared with B5, C2, and D3. § P < 0.05, as compared with other viruses. k P < 0.01, as compared with A2, C2, and D3. ¶ P < 0.01, as compared with A2 and C2. # P < 0.05, as compared with A2 and C2. P value greater than 0.05 is not displayed. **Productive replication was only established in HepG2-NTCP cells using the HepAD38-derived virus.
DIFFERENTIAL ACTIVATION OF IFN-a SIGNALING AND ISG INDUCTION WAS OBSERVED IN PHH, dHepaRG, AND HepaG2-NTCP CELLS
Because the efficacy of IFN-a for inhibition of HBV replication significantly varied among the three infection cell-culture models, and it remains controversial whether the HepG2 cells (from which HepG2-NTCP was generated) were defective in IFN-a signaling, (24, 25) we further compared the IFN responses among the three cell models to understand the difference in anti-HBV activity. IFN-a-induced phosphorylation of STAT1 and STAT2 was clearly detected in all three types of cells in a dose-dependent manner, 000 vge) , respectively, and further treated with IFN-a (20, 100, and 500 U/mL) for 9 days from day 3 post viral infection (A). The anti-HBV effect of IFN-a on secretion of HBsAg, HBeAg, and HBV DNA at day 12 was evaluated, and no cytotoxicity was observed after treatment (B). Anti-HBV effect of IFN-a (20, 100, and 500 U/mL) in HepG2-NTCP on genotype D that derived from HepAD38 cells was evaluated and compared with the effect in PHH and dHepaRG cells (C). Statistical analysis was performed with the Student t test. Data are shown as mean 6 SD (n 5 3). **P < 0.01; *P < 0.05; ns, P > 0.05. with similar levels following normalization to the baseline expression of STAT1 and STAT2 (Fig. 5A) . However, the three cell models were distinct in the expression pattern of ISGs. Particularly, whereas the induction of primary response ISGs, such as 2 0 -5 0 -oligoadenylate synthetase 1 (OAS1), interferoninduced transmembrane protein (IFITM) 2, STAT1, and IRF9, in HepG2-NTCP cells was comparable to that in PHH and dHepaRG, ISGs including C-X-C motif chemokine 10 (CXCL10), guanylate binding protein (GBP) 5, GBP1, and tryptophanyl-tRNA synthetase (WARS), which have been reported to be associated with the IFN-a responses in patients, (26, 27) were either absent or weakly expressed in HepG2-NTCP cells. The expression levels of APOBEC3G (A3G), ISG20, and APOBEC3A, which have been shown to have anti-HBV activities, were also lower in HepG2-NTCP cells than that in PHH and dHepaRG cells (Fig. 5B,C and Supporting Fig. S6 ). Considering that the actions of IFN-a are closely associated with the cell-surface receptor concentrations and a much higher number of IFNAR receptors is associated with antiproliferative, rather than antiviral, activity, (28, 29) we further examined the expression of IFNAR1, IFNAR2, TYK2, and JAK1. The results showed that these signaling molecules were expressed highly in HepG2-NTCP, but at a much lower level in PHH (Fig 5D) , which might contribute to the differential induction pattern of ISGs and antiviral effects. Furthermore, we showed that the induction of APO-BEC3G and ISG20 was abolished in PHH in the presence of CHX, a eukaryote protein synthesis inhibitor (Fig. 5E) , which suggested that the induction of a subset of genes that depends on primary protein synthesis is intact in PHH, but is partially incompetent in HepG2-NTCP cells, and this might be associated with the poor anti-HBV effect of IFN-a in HepG2-NTCP cells.
REDUCTION OR PROMOTION OF THE CELLULAR IFN RESPONSE ATTENUATED OR IMPROVED THE ANTI-HBV EFFICACY OF IFN-a IN HEPATOCYTES, RESPECTIVELY
To confirm that the differential cellular interferon responses are associated with the efficacy of IFN-a against HBV, we further examined whether the inhibitory capacity of IFN-a on HBV replication could be manipulated by reduction or promotion of cellular IFN responses. By using a JAK inhibitor (tofacitinib), IFNa-activated STAT1 and STAT2 phosphorylation and ISGs induction were intensively inhibited in PHH (Fig. 6A) , and, as expected, the IFN-a-mediated inhibition of HBV replication and induction levels of ISGs were significantly decreased (Fig. 6B) . Moreover, treatment of HepG2-NTCP cells with IFN-a14, one of the human IFN-a subtypes with the highest binding affinity to IFNAR1 and IFNAR2 (30) and the most potency in anti-HIV actions, (19, 31) induced higher expression of IFITM1 and significant expression of ISG20, GBP5, and tumor necrosis factor (ligand) superfamily, member 13B (TNFSF13B) (Fig. 6C ), which were absent or weakly induced upon treatment of the commonly used IFN-a (IFN-a2). More interestingly, along with the induction of ISGs, significant reduction of HBV DNA and HBeAg was observed in HepG2-NTCP cells and the IC 50 value of IFN-a14 for HBV inhibition was 10-to 100-fold lower than that of IFN-a (Fig. 6D) . Taken together, these results suggest that the intrinsic cellular response of host hepatocyte to IFN-a is closely associated with the inhibitory capacity of IFN-a on HBV replication, and promotion of IFN response in HepG2-NTCP cells by strong stimulation could significantly improve the efficacy of IFN-a against HBV.
Discussion
To achieve more effective personalized medicine and optimal cost-effectiveness, a number of prognostic parameters for prediction of the sustained response following IFN treatment have been developed. (7, 32) However, therapeutic regimens based on these parameters have not shown greatly improved response rates to IFN treatment. One of the reasons behind the lowconfidence prediction is a lack of experimental data that comprehensively characterize host and viral factors involving the effectiveness of IFN-a against HBV. With the development of cell-culture-based HBV infection models, (16, 17) we now have better tools to examine the sensitivity of HBV to IFN-a at the cellular and molecular levels.
This study focused on the role of HBV genotypes in affecting the effectiveness of IFN-a in hepatocytes, which, in the clinic, has been shown to be an important factor associating with the outcome of IFN treatment. The inhibitory capacity of IFN-a on HBV replication in HBV-infected cells was found to be FIG. 6 . Association between the cellular interferon response and the efficacy of IFN-a against HBV. The effect of IFN-a treatment on the secretion of HBV DNA from PHH was evaluated in the absence or presence of the JAK inhibitor I (Tofacitinib, 5 lM) (A,B). IFN-a14-or IFN-a2-induced expression of indicated genes (C) and the inhibitory effect of IFNs on HBV replication were examined in HepG2-NTCP cells (D). Statistical analysis was performed with the Student t test. Data are shown as mean 6 SD (n 5 3). **P < 0.01; *P < 0.05; ns, P > 0.05. Abbreviation: ns, not significant; p-STAT1, phosphor-STAT1; p-STAT2, phosphor-STAT2.
generally similar among genotypes A2, B5, C2, and D3; however, it was strikingly different among three cell-culture-based HBV infection models. Moreover, different cell models exhibited differential responses to IFN-a, and suppression or promotion of the cellular IFN response significantly attenuated or improved the inhibitory capacity of IFN-a on HBV replication, respectively. These results indicate that, compared to the viral genotypes, the host response to IFN-a may play a more dominant role in affecting the responsiveness of HBV to IFN-a in hepatocytes. Considering that the antiviral effects of IFN-a on human hepatocytes, without immune cell responses, was reported to be sufficient to induce sustained responsiveness and trigger substantial HBV antigen decline, (14) our study provides insights into the mechanism of the resistance of HBV to IFN-a therapy by showing the potential importance of the cellular IFN-a responsiveness, rather than the viral genotypes, in determining the outcome of IFN-a-based treatment of HBV infection.
Evidence from clinics has suggested an association between the effectiveness of IFN-a therapy for treatment of HBV infection and the HBV genotype. Therapy is most effective for patients infected with HBV genotype A2 (compared with genotype D) (8) and least effective for patients infected with HBV genotype C (compared with genotype B), irrespective of whether the IFN used was conventional or pegylated. The reasons for these differences remain unknown, but, notably, differences in IFN response of HBV genotype A2 and the genotypes B and C may relate to the fact that genotype A2 is mostly adult acquired whereas genotypes B and C are transmitted at birth or in very early childhood in a large proportion of Asian patients. The differential IFN response observed among these patients might be partially a reflection of the transmission-related immune tolerance or the host genetic polymorphisms, rather than the viral genotypes. Nonetheless, genotype D is often adult acquired, yet patients infected with this genotype respond poorest to IFN treatment. Although our results here showed that the sensitivity of HBV to IFN-a in human hepatocyte culture systems is similar across distinct genotypes, considering that the immune modulating function of IFN-a may also play important role in induction of favorable treatment response, (33) the role of HBV genotype in IFN-a therapeutic efficacy in the clinic cannot be ruled out.
Another possibility is that although we did not observe significant differences in the responsiveness of HBV genotypes to IFN-a in hepatocytes, the modulating activity of the viral HBs and hepatitis B e antigens on the functions of immune cells (34, 35) and the propensity to develop mutations previously associated with impaired IFN responses, such as the basal core promoter mutations, (36) may differ among HBV genotypes, which will lead to the variation in HBV replication, antigens production, and secretion. (20, 37) Our studies were restricted to wild-type HBV, for a limited time period. Here, different levels of HBV replication and antigen expression among HBV genotypes in HBV-infected cells with the same viral genome equivalent per cell were observed. Because it is difficult to investigate immune modulatory effects using current in vitro systems, new models are required to investigate associations between virological differences across genotypes and the genotyperelated differences in responsiveness to IFN-a. In addition, in the clinic, genotype-specific sensitivity might first become apparent only following long-term treatment, for example, attributed to differential propensity to acquire mutations that may mediate resistance; again, this is challenging to address in HBV cell-culture systems with limited culture duration. Similarly, for HCV, where genotype is strongly associated with differential response rates in the clinic, it has been difficult to identify genetic correlates of differential sensitivity to IFN in vitro. (38, 39) This may be attributed to IFN acting on various cell factors and not by a single well-defined mechanism, enabling the virus to escape using different mechanisms. Furthermore, it should be noted that, in general, only one isolate per genotype was included in our study, which is likely not entirely representative. In addition, because of the poor infectivity of B1 and B2 clones in our system, B5 was used here as a representative clone of genotype B; however, this subtype is not an Asian genotype, but actually localized to Alaska/South America.
Compared to the subtle differences in IFN sensitivity observed among genotypes, it was clear that higher HBV replication levels lead to lower sensitivity of HBV to IFN-a (Fig. 2E) . We believe this reflects the clinical observation that higher viral load is associated with poor responsiveness to IFN-a, which might be the result of stronger antagonism of IFN-a activity (34, 40, 41) as well as the dispersed distribution of ISGs. It has been reported that IFN-amediated control of HBV infection involves epigenetic suppression of cccDNA transcription and inhibition of viral replication. (42) (43) (44) In addition, a recent report showed that high-dose IFN-a noncytopathically reduced cccDNA levels in PHH and dHepaRG cells. (23) Unlike this report, in our system, IFN-a did not significantly reduce HBV cccDNA at the concentrations for which the markers of viral transcription and replication were strongly reduced, which supports the notion that the major effect of IFN-a against HBV is the suppression of viral transcription and replication, (14, (43) (44) (45) and only very-high-dose IFN-a may reduce the cccDNA. (23) Further studies, though technically difficult, are required to determine the physiological efficiency of IFN-a-mediated cccDNA loss in the context of IFN-based HBV therapies, and whether such loss of cccDNA is completely noncytopathic or is relative to IFN-ainduced cell death, proliferation, or immunomodulatory effect should be carefully evaluated. Notably, as a DNA virus, HBV is theoretically less responsive than RNA viruses, such as HCV, (27, 46) and the mechanisms responsible for IFN-a treatment responses are different in HBV and HCV. (27, 42, 47) Moreover, HBV was shown to lack an IFN sensitivitydetermining region. (48) Thus, more precise definition of the mechanisms by which IFN-a inhibits HBV replication will further clarify the factors involved in HBV resistance to IFN-a. Because significant differences in the IC 50 value of IFN-a for inhibition of HBV replication were observed among the infection models as PHH < dHepaRG < HepG2-NTCP, we further compared the response of host cells themselves to IFN-a among the three cell models. We found that the expression of ISGs were partially incompetent in HepG2-NTCP cells. In particular, a set of ISGs identified to be related to the IFN responses by transcriptome analysis in liver biopsies of CHB patients, (26, 27) including CXCL10, GBP5, TNFSF13B, and WARS, were robustly induced by IFN-a in PHH and dHepaRG cells, but hardly or only slightly induced in HepG2-NTCP cells. Previous reports suggested that although the HepG2-derived cells could mount antiviral IFN responses (15, 49) and have the positive feedback mechanisms in the IFN signaling, (25) they might lack secondary pathways, which are responsible for the induction of secondary IFN response genes. (24) Our data support the notion that the primary IFN signaling activation and ISG induction are intact, but do not translate into anti-HBV effect (15) in HepG2-NTCP cells, whereas the induction of a certain subset of ISGs is impaired or deficient in the cells. Moreover, we showed that the impaired ISGs induction in HepG2-NTCP cells could be restored or enhanced by using IFN-a14 and this was accompanied by the reduction of HBV replication, suggesting that the magnitude of cellular IFN responses may play an important role in IFN treatment response. It will be interesting to further characterize the key molecule(s) and pathway(s) responsible for the anti-HBV effect of IFN-a14 and to investigate the contribution of the induction of a certain subset of ISGs to IFN-mediated inhibition of HBV replication. Altogether, these results deepen our understanding of the mode of anti-HBV actions of IFN-a and may facilitate the identification of novel markers of the host responsiveness to IFN-a in patients.
